Pilot randomized controlled trial evaluating the effect of hypertonic saline with and without hyaluronic acid in reducing inflammation in cystic fibrosis

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 29, Issue 6, 2016, Pages 482-489

  Brivio, Anna ^a   Conese, Massimo ^b   Gambazza, Simone ^a   Biffi, Arianna ^a   Tirelli, Amedea Silvia ^c   Russo, Maria ^a   Foà, Michaela ^a   Colombo, Carla ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Clinical trial; Cystic fibrosis; Cytokines; Hyaluronic acid; Hypertonic saline; Lung function

Indexed keywords

HYPERTONIC SALINE PLUS HYALURONIC ACID; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; RESPIRATORY TRACT AGENT; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTIINFLAMMATORY AGENT; AUTACOID; CYTOKINE; DRUG COMBINATION; HYALURONIC ACID; SODIUM CHLORIDE;

ADOLESCENT; AGE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; PILOT STUDY; PREVALENCE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFLAMMATION; SALTINESS; THROAT IRRITATION; CHILD; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; ITALY; LUNG; METABOLISM; NEBULIZER; PATHOPHYSIOLOGY; PATIENT PREFERENCE; SPUTUM; TIME FACTOR; TREATMENT OUTCOME; VITAL CAPACITY; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADOLESCENT; ANTI-INFLAMMATORY AGENTS; CHILD; CYSTIC FIBROSIS; CYTOKINES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; HYALURONIC ACID; INFLAMMATION MEDIATORS; ITALY; LUNG; MALE; NEBULIZERS AND VAPORIZERS; PATIENT PREFERENCE; PILOT PROJECTS; SALINE SOLUTION, HYPERTONIC; SPUTUM; TIME FACTORS; TREATMENT OUTCOME; VITAL CAPACITY; YOUNG ADULT;

EID: 85002825140     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2015.1256     Document Type: Article

References (34)

1. Boucher RC: Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med. 2007;261:5-16.
2. Gifford AM, and Chalmers JD: The role of neutrophils in cystic fibrosis. Curr Opin Hematol. 2014;21:16-22.
3. Hilliard TN, Regamey N, Shute JK, Nicholson AG, Alton EW, Bush A, and Davies JC: Airway remodelling in children with cystic fibrosis. Thorax. 2007;62:1074-1080.
4. Anderson P: Emerging therapies in cystic fibrosis. Ther Adv Respir Dis. 2010;4:177-185.
5. Eng PA, Morton J, Douglass JA, Riedler J, Wilson J, and Robertson CF: Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol. 1996;21:77-83.
6. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, and Boucher RC: Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 2006;354:241-250.
7. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, and Bye PT: A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006;354: 229-240.
8. Wark P, and McDonald VM: Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev. 2009: CD001506.
9. Ballmann M, and von der Hardt H: Hypertonic saline and recombinant human DNase: A randomised cross-over pilot study in patients with cystic fibrosis. J Cyst Fibros. 2002;1: 35-37.
10. Heijerman H, Westerman E, Conway S, Touw D, and Doring G: Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus. J Cyst Fibros. 2009;8:295-315.
11. Elkins MR, and Bye PT: Inhaled hypertonic saline as a therapy for cystic fibrosis. Curr Opin Pulm Med. 2006;12: 445-452.
12. Turino GM, and Cantor JO: Hyaluronan in respiratory injury and repair. Am J Respir Crit Care Med. 2003;167: 1169-1175.
13. Cantor JO, Shteyngart B, Cerreta JM, Liu M, Armand G, and Turino GM: The effect of hyaluronan on elastic fiber injury in vitro and elastase-induced airspace enlargement in vivo. Proc Soc Exp Biol Med. 2000;225: 65-71.
14. Cantor JO, and Turino GM: Can exogenously administered hyaluronan improve respiratory function in patients with pulmonary emphysema? Chest. 2004;125:288-292.
15. Gavina M, Luciani A, Villella VR, Esposito S, Ferrari E, Bressani I, Casale A, Bruscia EM, Maiuri L, and Raia V: Nebulized hyaluronan ameliorates lung inflammation in cystic fibrosis mice. Pediatr Pulmonol. 2013;48:761-771.
16. Buonpensiero P, De Gregorio F, Sepe A, Di Pasqua A, Ferri P, Siano M, Terlizzi V, and Raia V: Hyaluronic acid improves "pleasantness" and tolerability of nebulized hy-pertonic saline in a cohort of patients with cystic fibrosis. Adv Ther. 2010;27:870-878.
17. Ros M, Casciaro R, Lucca F, Troiani P, Salonini E, Favilli F, Quattrucci S, Sher D, and Assael BM: Hyaluronic acid improves the tolerability of hypertonic saline in the chronic treatment of cystic fibrosis patients: A multicenter, randomized, controlled clinical trial. J Aerosol Med Pulm Drug Deliv. 2014;27:133-137.
18. Cresta F, Naselli A, Favilli F, and Casciaro R: Inhaled hypertonic saline+hyaluronic acid in cystic fibrosis with asthma-like symptoms: A new therapeutic chance. BMJ Case Rep. 2013;2013.
19. Furnari ML, Termini L, Traverso G, Barrale S, Bonaccorso MR, Damiani G, Piparo CL, and Collura M: Nebulized hypertonic saline containing hyaluronic acid improves tol-erability in patients with cystic fibrosis and lung disease compared with nebulized hypertonic saline alone: A prospective, randomized, double-blind, controlled study. Ther Adv Respir Dis. 2012;6:315-322.
20. Standardization of spirometry, 1994 update. American Thoracic Society: Am J Respir Crit Care Med. 1995;152: 1107-1136.
21. Colombo C, Faelli N, Tirelli AS, Fortunato F, Biffi A, Claut L, Cariani L, Dacco V, Prato R, and Conese M: Analysis of inflammatory and immune response biomarkers in sputum and exhaled breath condensate by a multi-parametric biochip array in cystic fibrosis. Int J Immunopathol Pharmacol. 2011;24:423-432.
22. Julious SA: Sample size of 12 per group rule of thumb for a pilot study. Pharmaceut Statist. 2005;4:287-291.
23. Schulz KF, Altman DG, and Moher D: CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8:18.
24. Dmello D, Nayak RP, and Matuschak GM: Stratified assessment of the role of inhaled hypertonic saline in reducing cystic fibrosis pulmonary exacerbations: A retrospective analysis. BMJ Open. 2011;1:e000019.
25. Cohen-Cymberknoh M, Shoseyov D, and Kerem E: Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med. 2011;183:1463-1471.
26. King M, Dasgupta B, Tomkiewicz RP, and Brown NE: Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I. Am J Respir Crit Care Med. 1997;156:173-177.
27. Wills PJ, Hall RL, Chan W, and Cole PJ: Sodium chloride increases the ciliary transportability of cystic fibrosis and bronchiectasis sputum on the mucus-depleted bovine trachea. J Clin Invest. 1997;99:9-13.
28. Havasi V, Hurst CO, Briles TC, Yang F, Bains DG, Has-sett DJ, and Sorscher E: Inhibitory effects of hypertonic saline on P. aeruginosa motility. J Cyst Fibros. 2008;7: 267-269.
29. Michon AL, Jumas-Bilak E, Chiron R, Lamy B, and Marchandin H: Advances toward the elucidation of hy-pertonic saline effects on Pseudomonas aeruginosa from cystic fibrosis patients. PLoS One. 2014;9:e90164.
30. Bye PT, and Elkins MR: Other mucoactive agents for cystic fibrosis. Paediatr Respir Rev. 2007;8:30-39.
31. Dhooghe B, Noel S, Huaux F, and Leal T: Lung inflammation in cystic fibrosis: Pathogenesis and novel therapies. Clin Biochem. 2014;47:539-546.
32. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, and Dake MD: Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med. 2001;7: 425-429.
33. Shoki AH, Mayer-Hamblett N, Wilcox PG, Sin DD, and Quon BS: Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations. Chest. 2013;144:1659-1670.
34. Colombo C, Costantini D, Rocchi A, Cariani L, Garlaschi ML, Tirelli S, Calori G, Copreni E, and Conese M: Cyto-kine levels in sputum of cystic fibrosis patients before and after antibiotic therapy. Ped Pulmunol. 2005;40:15-21.